Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium bifidum bf-688
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium bifidum Bf-688 is a specific strain of probiotic bacteria being investigated as an adjunctive treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in children. Developed by Glac Biotech, this live microorganism is administered orally as a supplement. Clinical studies, including an open-label trial and a randomized, double-blind, placebo-controlled trial (NCT04958460) conducted in Taiwan, have shown that Bf-688 can improve ADHD symptoms like inattention and hyperactivity, enhance neuropsychological performance in visual and auditory attention tests, and lead to weight gain in some patients. Its mechanism of action is believed to be through the gut-brain axis; it modulates the composition of the gut microbiota, notably by altering the Firmicutes to Bacteroidetes ratio, and may influence neurotransmitter pathways and reduce N-Glycan biosynthesis.
- Brand names
- PRONULIFE GUARD 688
Beyond the preview
Go deeper on bifidobacterium bifidum bf-688.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium bifidum bf-688.